2584-48-7

Basic information

• Product Name: N-methyl-3-oxo-N-phenylbutyramide
• Synonyms: N-methyl-3-oxo-N-phenylbutyramide;3-keto-N-methyl-N-phenyl-butyramide;Butanamide, N-methyl-3-oxo-N-phenyl-;MFCD00129141
• CAS NO: 2584-48-7
• Molecular Formula: C₁₁H₁₃NO₂
• Molecular Weight: 191.22642
• EINECS: 219-961-4
• Mol File: 2584-48-7.mol
• Article Data: 16

Chemical Properties

• Boiling Point: 301.4°Cat760mmHg
• Flash Point: 126.3°C
• Appearance: /
• Density: 1.117g/cm³
• Vapor Pressure: 0.00106mmHg at 25°C
• Refractive Index: 1.549
• CAS DataBase Reference: N-methyl-3-oxo-N-phenylbutyramide(CAS DataBase Reference)
• NIST Chemistry Reference: N-methyl-3-oxo-N-phenylbutyramide(2584-48-7)
• EPA Substance Registry System: N-methyl-3-oxo-N-phenylbutyramide(2584-48-7)

Safety Data

• Hazardous Substances Data: 2584-48-7(Hazardous Substances Data)

Usage

General Description

N-methyl-3-oxo-N-phenylbutyramide is a chemical compound with the molecular formula C12H13NO2. It is a derivative of butyramide, containing a phenyl group and a methyl group attached to the nitrogen atom. N-methyl-3-oxo-N-phenylbutyramide is a synthetic intermediate used in the production of pharmaceuticals and agrochemicals. It has potential applications in the field of medicinal chemistry, particularly in the development of new drugs. N-methyl-3-oxo-N-phenylbutyramide may also have industrial uses as a precursor or intermediate in chemical synthesis processes. Overall, this compound has important implications for various industries and scientific research endeavors.

InChI:InChI=1/C11H13NO2/c1-9(13)8-11(14)12(2)10-6-4-3-5-7-10/h3-7H,8H2,1-2H3

Upstream product

• 105-45-3 acetoacetic acid methyl ester 
• 100-61-8 N-methylaniline 
• 1354971-57-5 C₁₁H₁₂BrNO₂ 
• 5394-63-8 2,2,6-trimethyl-4H-1,3-dioxin-4-one 
• 691-45-2 acetylketene 
• 674-82-8 4-methyleneoxetan-2-one 
• 141-97-9 ethyl acetoacetate 

Downstream Products

• 175658-16-9 α-(phenylthio)-N-methyl-N-phenylacetamide 
• 848505-01-1 N-methyl-N-phenyl-2-(phenylselanyl)acetamide 
• 1354971-54-2 (±)-3-acetyl-3-benzyl-1-methylindolin-2-one 
• 6759-51-9 6-amino-1,4-dimethylquinolin-2(1H)-one 
• 6760-41-4 1,4-dimethyl-6-nitroquinolin-2(1H)-one 
• 875-30-9 1,3-dimethylindole 
• 857559-02-5 N,2-dimethyl-3-oxo-N-phenylbutanamide 
• 1643654-90-3 (2S,3S)-2-acetyl-N-methyl-4-nitro-N,3-diphenylbutanamide 
• 63238-14-2 4-amino-N-methyl-2-(methylthio)-N-phenylthiazole-5-carboxamide 
• 1354971-57-5 C₁₁H₁₂BrNO₂ 
• 93476-41-6 3-hydroxy-1,4-dimethylquinolin-2(1H)-one 
• 1436432-60-8 2-hydroxy-N-methyl-3-oxo-N-phenylbutanamide 
• 1309222-41-0 N,6-methyl-N,4-diphenyl-2-thioxo-1,2,3,4-tetrahydropyrimidine-5-carboxamide 

Relevant articles and documents

-

-

Design of a Chemical Probe for the Bromodomain and Plant Homeodomain Finger-Containing (BRPF) Family of Proteins

The bromodomain and plant homeodomain finger-containing (BRPF) family are scaffolding proteins important for the recruitment of histone acetyltransferases of the MYST family to chromatin. Here, we describe NI-57 (16) as new pan-BRPF chemical probe of the bromodomain (BRD) of the BRPFs. Inhibitor 16 preferentially bound the BRD of BRPF1 and BRPF2 over BRPF3, whereas binding to BRD9 was weaker. Compound 16 has excellent selectivity over nonclass IV BRD proteins. Target engagement of BRPF1B and BRPF2 with 16 was demonstrated in nanoBRET and FRAP assays. The binding of 16 to BRPF1B was rationalized through an X-ray cocrystal structure determination, which showed a flipped binding orientation when compared to previous structures. We report studies that show 16 has functional activity in cellular assays by modulation of the phenotype at low micromolar concentrations in both cancer and inflammatory models. Pharmacokinetic data for 16 was generated in mouse with single dose administration showing favorable oral bioavailability.

QUINOLONES AS INHIBITORS OF CLASS IV BROMODOMAIN PROTEINS

The present invention provides compounds of formula (I) as described herein and pharmaceutically acceptable salts, hydrates and solvates thereof for use in medicine, for example in the treatment of acute myeloid leukaemia: